A certificate of analysis is useful when you can connect its results to the material you received and understand what was actually measured. A document headed “BPC-157, 99% purity” is only a starting point. The important questions are which sample was tested, what the analytical method could detect, and whether the result answers your research question.
This guide walks through those checks, including an illustrative chromatogram calculation and a practical way to handle incomplete documentation. The examples below are fictional. They are not results for a PFC product or a substitute for testing a received sample.
Start with three different questions
Identity asks whether the analytical evidence supports the claimed compound. Chromatographic purity describes the relative signals of components detected and separated by a particular method. Content asks how much of the intended peptide is present on a defined basis.
These measurements should not be collapsed into one percentage. A sample can produce a dominant HPLC peak without establishing the amount of BPC-157 in a vial. An LC-MS result consistent with an expected mass can support identity without quantifying every impurity. A quantitative assay can estimate content, but its meaning still depends on the reference material, sample preparation and calculation basis.
NIST's work on peptide quantification compares HPLC assay, quantitative NMR and amino-acid analysis. It illustrates why peptide content is a measurement problem of its own, rather than a number obtained by reading a chromatographic purity result. NIST peptide quantification study
Match the document to the received material
Before interpreting a graph, create a short record containing:
The compound name and stated chemical form, including any salt or counterion information.
The supplier lot, received-vial identifier and your own laboratory sample identifier.
The report number, issuing laboratory, issue date and revision, if any.
The sample description, submission date and test date where available.
The result, units, acceptance limit and method reference for each reported test.
Keep photographs of the received labels with the order record and original report. If your laboratory divides the material into new containers, preserve the relationship between those containers and the received sample.
A matching lot number is necessary for interpreting a lot-specific claim, but it does not independently establish how the tested sample was selected. Ask who submitted it, what it represented and whether the report concerns raw material, finished vials or a separately prepared reference sample. A genuine report for the wrong material cannot answer the question you are asking.
For example, suppose a report identifies “BPC-157 raw material, lot A,” while the received vials carry finished-product lot B. The next step is to request the documented relationship between those lots. Do not silently assume that a raw-material result also verifies vial filling, subsequent handling or the amount in each finished vial.
Read an HPLC result beyond the headline percentage
A useful chromatographic record includes the chromatogram, peak table and sufficient method information to interpret them. Look for the detection wavelength, column information, run conditions or an identifiable method reference, integration settings where relevant, and the basis used to calculate the reported purity.
Here is a simplified example. A peak table contains a main peak with area 985,000 and two other included peaks with areas 10,000 and 5,000. The total included area is 1,000,000. Simple area normalization therefore gives the main peak 98.5% of that total.
That calculation says nothing by itself about milligrams in a vial. It describes the included detector signals under the stated conditions. Before accepting the number, ask:
Were all relevant peaks included, and were any excluded as blanks, solvent signals or below a reporting threshold?
Is a small nearby peak separated from the main peak, or could it overlap?
Was the main peak assigned using adequate supporting evidence rather than simply choosing the largest peak?
Does the method use uncorrected peak area, a reference standard or response-factor corrections?
Different compounds can produce different detector responses. Waters documents how relative response factors are used to correct impurity areas in its chromatography software. A report should make clear whether such corrections apply rather than leave the reader to treat every area percentage as a mass percentage. Waters: impurity response factors
A clean-looking graph is not enough to resolve co-elution or components the method does not detect adequately. Conversely, a small additional peak is not, by itself, proof of a dangerous contaminant: identifying and quantifying it requires suitable evidence. The useful response to an unexplained feature is a technical question, not an accusation or a reassuring guess.
Read mass spectrometry as identity evidence
Mass spectrometry measures mass-to-charge ratio. Peptides may produce several charge states, so the number beside a spectral peak is not necessarily the neutral molecular mass. Deconvolution is one way to interpret a multiply charged spectrum and calculate the corresponding molecular mass. Agilent: spectral deconvolution
For a BPC-157 report, ask the laboratory to state the expected analyte, the observed result, the charge-state or deconvolution interpretation and the acceptance criterion. Check whether a quoted mass is monoisotopic or average mass before treating two differently expressed values as a contradiction. If the report mentions an adduct, request the assignment rather than adding or subtracting numbers yourself to force a match.
An intact-mass match supports a particular claim; it is not a complete sequence determination. Where sequence confirmation matters, suitable tandem mass spectrometry can provide fragment evidence. Agilent distinguishes peptide mass measurement by LC-MS from sequence confirmation using MS/MS fragmentation. The actual coverage and limitations still need to be stated for the sample. Agilent: peptide characterization
In a document review, a sensible conclusion may therefore be “the reported mass is consistent with the stated analyte under this method,” rather than “the entire identity and purity are proven.”
Clarify what a vial quantity means
A vial label and an analytical content result are different records. Ask whether a stated quantity refers to peptide content, material as received, or another defined basis. Water, counterions and formulation components can affect the relationship between total material mass and peptide mass.
NIST's peptide-purity research examines mass balance and other approaches to assigning peptide mass fraction. The broader lesson for procurement is simple: the quantity basis must be explicit. This does not mean every project needs every analytical technique. It means a project that depends on content needs a suitable content measurement, not a chromatogram relabeled as an assay. NIST: peptide mass-fraction measurement
Use specifications and test reports for different purposes
A specification states the properties and acceptance limits that material is expected to meet. A test report records measurements on an identified sample. Keep both where available, and do not present one as the other.
PFC's current documentation approach is explained in the quality and ordering FAQ. Product-specific specifications and available quality information should be checked for the item being considered. Do not assume that a seller-issued independent laboratory COA is included with every product or that a report about another sample verifies the material you receive.
Where the research requires independent confirmation, arrange testing of the received material with a suitably qualified laboratory. Agree the questions before commissioning the work: identity, impurity profile and content can require different measurements. Include the sample identifiers and expected chemical form in the laboratory brief, and retain the resulting report with your receipt records.
A practical review decision
Consider a fictional packet with a matching vial and report lot number, a 98.5% area-normalized HPLC result, and a mass result described as consistent with BPC-157. No quantitative content result is included.
A defensible review would record:
Document linkage: matching identifiers, with the sample-submission history still to be confirmed.
Chromatography: reported main-peak area percentage, subject to the stated method and integration.
Identity: mass-consistency evidence, not a blanket claim of complete sequence verification.
Content: not established by the supplied results.
Further work: request missing method or sample information; commission a suitable content assay if the study depends on it.
This is more useful than a single “pass” based on the largest number on the page. Acceptance should follow the project's predefined requirements. ICH Q2(R2) describes validation in terms of fitness for an intended purpose and distinguishes identity, assay and impurity measurements. Its pharmaceutical framework offers useful analytical principles here; citing it does not establish regulatory compliance or approval of a research product. ICH Q2(R2), final FDA guidance
Common questions
Does “99% HPLC purity” mean a 10 mg vial contains 9.9 mg of BPC-157?
No. That conclusion would confuse a detector-area result with a quantitative content measurement and assume a quantity basis that may not have been established.
Can I compare purity percentages from two laboratories?
Only after understanding the methods and reporting bases. Different separation, detection, integration and reporting practices can make headline numbers non-equivalent. Ask the laboratories to explain material differences before ranking the samples.
Does a genuine COA prove the received vial was tested?
No. Report authenticity and sample traceability are separate questions. A laboratory can confirm a report's authenticity while the connection to your vial still needs supporting records.
What should I do if information is missing?
List the specific gap and ask the document provider or testing laboratory to clarify it. Missing information is a reason to withhold an unsupported conclusion, not evidence by itself that the supplier committed fraud.
A COA does not by itself establish sterility, endotoxin status, biological potency or clinical suitability. This article is for research-documentation review only and provides no dosing, administration or human or animal use instructions.